Documents
-
- Download
- Title Pages_Contents
-
open access
-
- Download
- Chapter 2
-
open access
- Full text at publishers site
-
- Download
- Chapter 4
-
open access
- Full text at publishers site
-
- Download
- Chapter 5
-
open access
- Full text at publishers site
-
- Download
- Chapter 6
-
open access
- Full text at publishers site
-
- Download
- Chapter 7
-
open access
- Full text at publishers site
-
- Download
- Chapter 8
-
open access
- Full text at publishers site
-
- Download
- Chapter 9
-
open access
- Full text at publishers site
-
- Download
- Chapter 10
-
open access
-
- Download
- Chapter 11 Summary in English and in Dutch
-
open access
-
- Download
- Propositions
-
open access
In Collections
This item can be found in the following collections:
Platelet transfusions in patients with a hematological malignancy : improving the chain
The majority of platelet transfusions are given to patients with a hematological malignancy to prevent or treat bleeding complications. The adhered transfusion trigger for patients with an increased risk of bleeding varies among hematologists. Although almost 20.000 donors are HLA typed in the Netherlands, adequate transfusion support cannot be guaranteed for all immunized patients, especially not for patients from a non-Caucasian background.
From a clinical perspective, major hemorrhage is the most relevant outcome to measure effectiveness of platelet transfusions. We developed a model consisting of drop in hemoglobin, transfusion support, and CT-brain to enable the identification of major hemorrhage among leukemic patients in routinely recorded data.
In the Netherlands, the standard platelet concentrate is derived from buffy coats and resuspended in plasma or platelet additive solution (PAS) and can be stored for seven days. Storage...
The majority of platelet transfusions are given to patients with a hematological malignancy to prevent or treat bleeding complications. The adhered transfusion trigger for patients with an increased risk of bleeding varies among hematologists. Although almost 20.000 donors are HLA typed in the Netherlands, adequate transfusion support cannot be guaranteed for all immunized patients, especially not for patients from a non-Caucasian background.
From a clinical perspective, major hemorrhage is the most relevant outcome to measure effectiveness of platelet transfusions. We developed a model consisting of drop in hemoglobin, transfusion support, and CT-brain to enable the identification of major hemorrhage among leukemic patients in routinely recorded data.
In the Netherlands, the standard platelet concentrate is derived from buffy coats and resuspended in plasma or platelet additive solution (PAS) and can be stored for seven days. Storage has a negative effect on safety and efficacy of platelet transfusions.
Using routinely collected health care data, we demonstrated a lower risk of a positive blood culture after transfusion of platelet concentrates stored for five to seven days. Using the database of TRIP, we showed an increased risk of transfusion transmitted bacterial infections for platelet concentrates stored in PAS compared to those stored in plasma.
- All authors
- Kreuger, A.L.
- Supervisor
- Bom, J.G. van der
- Co-supervisor
- Middelburg, R.A.; Kerkhoffs, J.L.H.
- Committee
- Veelken, J.H.; Schutgens, R.E.G.; Juffermans, N.P.
- Qualification
- Doctor (dr.)
- Awarding Institution
- Faculty of Medicine, Leiden University Medical Center (LUMC) , Leiden University
- Date
- 2018-09-13
- ISBN (print)
- 9789493019249
Funding
- Sponsorship
- Sanquin, Chipsoft